This site is intended for healthcare professionals

Phase III ANDROMEDA study of subcutaneous Darzalex shows long term positive response in light chain amyloidosis.- Janssen Pharma

Read time: 1 mins
Last updated:28th Jun 2021
Published:29th May 2021
The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase III ANDROMEDA study, which evaluated Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of patients with newly diagnosed light chain (AL) amyloidosis.
Condition: Amyloidosis
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest